Mesenchymal Stem Cells-Derived Exosomes is under clinical development by AbelZeta and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mesenchymal Stem Cells-Derived Exosomes overview
The drug candidate is under development for the treatment of moderate to severe acute respiratory distress syndrome. It is administered through inhalation route as an aerosol and as intravenous bolus. The drug candidate comprises of exosomes derived from allogenic adipose mesenchymal stem cells(MSCs-Exo).
It was also under development for coronavirus(SARS-CoV-2 or Covid-19), dermatomyositis and dementia
AbelZeta overview
AbelZeta, formerly Cellular Biomedicine Group Inc, is a clinical-stage biopharmaceutical firm that develops and commercializes cell therapies. It focus on the therapeutic areas such as hematological cancers, solid tumors and inflammatory and immunological diseases. The company pipeline products include C-CAR039, C-CAR066, C-CAR088 for hematology malignancies; C-CAR168 for the treatment of inflammatory and immunological diseases; C-CAR031, C-CAR036, Armored CAR-T, C-TIL051 treats solid tumors. Its cell therapeutic platforms include chimeric antigen receptor t-cell (CAR-T) and tumor-infiltrating lymphocytes (TIL). It operates in Hong Kong, China and the US. AbelZeta is headquartered in Cupertino, California, the US.
For a complete picture of Mesenchymal Stem Cells-Derived Exosomes’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
